Skip to main content
Top
Published in: Rheumatology International 6/2019

01-06-2019 | Cohort Studies

ESSDAI activity index of the SJÖGRENSER cohort: analysis and comparison with other European cohorts

Authors: José Rosas, Carlos Sánchez-Piedra, Mónica Fernández-Castro, José Luis Andreu, Víctor Martínez-Taboada, Alejandro Olivé, SJÖGRENSER Group, part of the Spanish Society of Rheumatology Systemic Autoimmune Diseases Study Group (EASSER)

Published in: Rheumatology International | Issue 6/2019

Login to get access

Abstract

The objective of the study was to assess the ESSDAI index characteristics in the SJÖGRENSER cohort (Spanish Rheumatology Association’s registry of patients with Primary Sjögren Syndrome [PSS]). SJÖGRENSER is a prospective multicentric study on a cohort of Spanish patients with PSS who meet the 2002 American–European consensus from rheumatology units. 298 variables were studied in patients for the inclusion of the study from an anonymous list from each department. The ESSDAI (EULAR Sjögren’s syndrome disease activity index) includes 12 domains and measures systematic activity in PSS patients. Each domain is divided into 3–4 levels, (0: no activity; 1: low activity; 2: moderate activity; 3: high activity) and is attributed a weight. Each domain score is obtained by multiplying the activity level by the weight assigned. According to ESSDAI: low activity < 5; moderate activity 5–13, and high activity ≥ 14. ESSDAI was compared between several European PSS cohorts (EULAR, ASSES, GEAS, GRISS, Ducth). 437 patients were included from 33 Spanish rheumatology units. 95.2% were women with a median age of 58.63 years [p25–p75: 50.02–67.98 years] and average PSS evolution of 10.4 years (6–16 years). ESSDAI median on entering the study was 2 (0–4). 31% of patients had ESSDAI 0; low activity 49%, moderate activity 15%, and high activity 5%. Those with greater activity were the joint, haematological and biological domains, whereas the lung was the most affected organ with pleural and parenchymatous involvement. Unlike other European cohorts, the initial SJÖGRENSER cohort was characterised by low-zero systemic activity in 80% of patients, which differentiates it from other cohorts and provides a prospective study opportunity.
Literature
2.
go back to reference Moutsopoulos (1994) Sjögren’s syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 72:162–165CrossRefPubMed Moutsopoulos (1994) Sjögren’s syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 72:162–165CrossRefPubMed
3.
go back to reference Aagyropoulou O, Valentini E, Ferro F et al (2018) One year in review 2018: Sjögren's syndrome. Clin Exp Rheumatol 36(Suppl 112):27–28 Aagyropoulou O, Valentini E, Ferro F et al (2018) One year in review 2018: Sjögren's syndrome. Clin Exp Rheumatol 36(Suppl 112):27–28
4.
go back to reference Qin B, Wang J, Yang Z et al (2015) Epidemiology of primary Sjögren’s syndrome: A systematic review and meta-analysis. Ann Rheum Dis 74:1983–1989CrossRefPubMed Qin B, Wang J, Yang Z et al (2015) Epidemiology of primary Sjögren’s syndrome: A systematic review and meta-analysis. Ann Rheum Dis 74:1983–1989CrossRefPubMed
5.
go back to reference Seror R, Ravaud P, Bowman SJ et al (2010) EULAR Sjögren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren’s syndrome. Ann Rheum Dis 69:1103–1109CrossRefPubMed Seror R, Ravaud P, Bowman SJ et al (2010) EULAR Sjögren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren’s syndrome. Ann Rheum Dis 69:1103–1109CrossRefPubMed
6.
go back to reference Seror R, Bootsma H, Saraux A et al (2016) Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis 75:382–389CrossRefPubMed Seror R, Bootsma H, Saraux A et al (2016) Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis 75:382–389CrossRefPubMed
7.
go back to reference Souza FB, Porfirio GJ, Andriolo BN et al (2016) Rituximab effectiveness and safety for treating primary Sjögren’s Syndrome (pSS): systematic review and meta-analysis. PLoS One 11:e0150749CrossRefPubMedPubMedCentral Souza FB, Porfirio GJ, Andriolo BN et al (2016) Rituximab effectiveness and safety for treating primary Sjögren’s Syndrome (pSS): systematic review and meta-analysis. PLoS One 11:e0150749CrossRefPubMedPubMedCentral
8.
go back to reference Carubbi F, Cipriani P, Marelli A et al (2013) Efficacy and safety of rituximab treatment in early primary Sjögren’s syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther 15:R172CrossRefPubMedPubMedCentral Carubbi F, Cipriani P, Marelli A et al (2013) Efficacy and safety of rituximab treatment in early primary Sjögren’s syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther 15:R172CrossRefPubMedPubMedCentral
9.
go back to reference Mekinian A, Ravaud P, Hatron PY et al (2012) Efficacy of rituximab in primary Sjögren’s syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis 71:84–87CrossRefPubMed Mekinian A, Ravaud P, Hatron PY et al (2012) Efficacy of rituximab in primary Sjögren’s syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis 71:84–87CrossRefPubMed
10.
go back to reference Gottenberg JE, Cinquetti G, Larroche C et al (2013) Efficacy of rituximab in systemic manifestations of primary Sjögren’s syndrome: results in 78 patients of the autoimmune and Rituximab registry. Ann Rheum Dis 72:1026–1031CrossRefPubMed Gottenberg JE, Cinquetti G, Larroche C et al (2013) Efficacy of rituximab in systemic manifestations of primary Sjögren’s syndrome: results in 78 patients of the autoimmune and Rituximab registry. Ann Rheum Dis 72:1026–1031CrossRefPubMed
11.
go back to reference Meiners PM, Arends S, Brouwer E et al (2012) Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren’s syndrome treated with rituximab. Ann Rheum Dis 71:1297–1302CrossRefPubMed Meiners PM, Arends S, Brouwer E et al (2012) Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren’s syndrome treated with rituximab. Ann Rheum Dis 71:1297–1302CrossRefPubMed
12.
go back to reference Seror R, Mariette X, Bowman S et al (2010) Accurate detection of changes in disease activity in primary Sjögren’s syndrome by the European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index. Arthritis Care Res (Hoboken) 62:551–558CrossRef Seror R, Mariette X, Bowman S et al (2010) Accurate detection of changes in disease activity in primary Sjögren’s syndrome by the European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index. Arthritis Care Res (Hoboken) 62:551–558CrossRef
13.
go back to reference Ramos-Casals M, Solans R, Rosas J et al (2008) Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine 87:210–219CrossRefPubMed Ramos-Casals M, Solans R, Rosas J et al (2008) Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine 87:210–219CrossRefPubMed
14.
go back to reference Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558CrossRefPubMedPubMedCentral Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558CrossRefPubMedPubMedCentral
15.
go back to reference Fernández Castro M, Andreu JL, Sánchez-Piedra C et al (2016) Sjögren-SER: National registry of the Spanish Society of Rheumatology of patients with primary Sjögren syndrome: objectives and methodology. Reumatol Clin 12:184–189CrossRefPubMed Fernández Castro M, Andreu JL, Sánchez-Piedra C et al (2016) Sjögren-SER: National registry of the Spanish Society of Rheumatology of patients with primary Sjögren syndrome: objectives and methodology. Reumatol Clin 12:184–189CrossRefPubMed
16.
18.
go back to reference Ramos-Casals M, Brito-Zerón P, Solans R et al (2014) Systemic involvement in primary Sjögren’s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology 53:321–331CrossRefPubMed Ramos-Casals M, Brito-Zerón P, Solans R et al (2014) Systemic involvement in primary Sjögren’s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology 53:321–331CrossRefPubMed
19.
go back to reference Quartuccio L, Baldini C, Priori R et al (2017) Cryoglobulinemia in Sjögren's Syndrome: a disease subset that links higher systemic disease activity, autoimmunity, and local B cell proliferation in mucosa-associated lymphoid tissue. J Rheumatol 44:1179–1183CrossRefPubMed Quartuccio L, Baldini C, Priori R et al (2017) Cryoglobulinemia in Sjögren's Syndrome: a disease subset that links higher systemic disease activity, autoimmunity, and local B cell proliferation in mucosa-associated lymphoid tissue. J Rheumatol 44:1179–1183CrossRefPubMed
20.
go back to reference Risselada AO, Kruize AA, Bijlsma JWJ (2012) Clinical applicability of the EULAR Sjögren’s syndrome disease activity index: a cumulative ESSDAI score adds in describing disease severity. Ann Rheum Dis 71:631–632CrossRefPubMed Risselada AO, Kruize AA, Bijlsma JWJ (2012) Clinical applicability of the EULAR Sjögren’s syndrome disease activity index: a cumulative ESSDAI score adds in describing disease severity. Ann Rheum Dis 71:631–632CrossRefPubMed
21.
go back to reference Moerman RV, Arends S, Meiners PM et al (2014) EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomized controlled trial. Ann Rheum Dis 73:472–474CrossRefPubMed Moerman RV, Arends S, Meiners PM et al (2014) EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomized controlled trial. Ann Rheum Dis 73:472–474CrossRefPubMed
22.
go back to reference Mariette X, Roux S, Zhang J et al (2003) The level of BLyS (BAFF) correlates with the titer of autoantibodies in human Sjögren’s syndrome. Ann Rheum Dis 62:168–171CrossRefPubMedPubMedCentral Mariette X, Roux S, Zhang J et al (2003) The level of BLyS (BAFF) correlates with the titer of autoantibodies in human Sjögren’s syndrome. Ann Rheum Dis 62:168–171CrossRefPubMedPubMedCentral
23.
go back to reference De Vita S, Quartuccio L, Seror R et al (2015) Efficacy and safety of belimumab given for 12 months in primary Sjögren’s syndrome: the BELISS open-label phase II study. Rheumatology. (Oxford) 54:2249–2256 De Vita S, Quartuccio L, Seror R et al (2015) Efficacy and safety of belimumab given for 12 months in primary Sjögren’s syndrome: the BELISS open-label phase II study. Rheumatology. (Oxford) 54:2249–2256
24.
go back to reference Quartuccio L, Salvin S, Corazza L et al (2016) Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren’s syndrome: follow-up after the end of the phase II open-label BELISS study. Clin Exp Rheumatol 34:311–314PubMed Quartuccio L, Salvin S, Corazza L et al (2016) Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren’s syndrome: follow-up after the end of the phase II open-label BELISS study. Clin Exp Rheumatol 34:311–314PubMed
25.
go back to reference Meiners PM, Vissink A, Kroese FG et al (2014) Abatacept treatment reduces disease activity in early primary Sjögren’s syndrome (open-label proof of concept ASAP study). Ann Rheum Dis 73:1393–1396CrossRefPubMed Meiners PM, Vissink A, Kroese FG et al (2014) Abatacept treatment reduces disease activity in early primary Sjögren’s syndrome (open-label proof of concept ASAP study). Ann Rheum Dis 73:1393–1396CrossRefPubMed
26.
go back to reference Dumusc A, Wan-Fai NG, James K et al (2018) Comparison of ESSDAI and ClinESSDAI in potential optimization of trial outcomes in primary Sjögren’s syndrome: examination of data from the UK Primary Sjögren’s Syndrome Registry. Swiss Med Wkly 148:w14588PubMed Dumusc A, Wan-Fai NG, James K et al (2018) Comparison of ESSDAI and ClinESSDAI in potential optimization of trial outcomes in primary Sjögren’s syndrome: examination of data from the UK Primary Sjögren’s Syndrome Registry. Swiss Med Wkly 148:w14588PubMed
Metadata
Title
ESSDAI activity index of the SJÖGRENSER cohort: analysis and comparison with other European cohorts
Authors
José Rosas
Carlos Sánchez-Piedra
Mónica Fernández-Castro
José Luis Andreu
Víctor Martínez-Taboada
Alejandro Olivé
SJÖGRENSER Group, part of the Spanish Society of Rheumatology Systemic Autoimmune Diseases Study Group (EASSER)
Publication date
01-06-2019
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 6/2019
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-019-04285-w

Other articles of this Issue 6/2019

Rheumatology International 6/2019 Go to the issue